8 years of historical data (2017–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioNTech SE currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $27.7B | $27.4B | $25.6B | $37.5B | $67.0B | $20.3B | $7.2B | — | — |
| Enterprise Value | $16.4B | $17.9B | $14.2B | $23.9B | $65.6B | $19.3B | $6.7B | — | — |
| P/E Ratio → | -33.74 | — | 27.56 | 4.05 | 6.26 | 1430.18 | — | — | — |
| P/S Ratio | 8.52 | 9.96 | 6.71 | 2.17 | 3.53 | 42.01 | 65.98 | — | — |
| P/B Ratio | 1.16 | 1.41 | 1.27 | 1.87 | 5.63 | 14.77 | 14.52 | — | — |
| P/FCF | — | — | 5.49 | 2.84 | 91.00 | — | — | — | — |
| P/OCF | 112.90 | 131.89 | 4.77 | 2.76 | 75.25 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.50 | 3.71 | 1.38 | 3.45 | 40.00 | 61.88 | — | — |
| EV / EBITDA | — | — | 16.22 | 1.87 | 4.27 | — | — | — | — |
| EV / EBIT | — | — | 11.87 | 1.84 | 4.39 | — | — | — | — |
| EV / FCF | — | — | 3.04 | 1.81 | 89.11 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
BioNTech SE earns an operating margin of -47.8%. Operating margins have compressed from 73.0% to -47.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -3.4% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.3% | 80.3% | 84.3% | 82.7% | 84.7% | 87.7% | 84.0% | 89.3% | 84.9% |
| Operating Margin | -47.8% | -47.8% | 18.1% | 73.0% | 80.5% | -17.1% | -167.1% | -42.2% | -99.5% |
| Net Profit Margin | -24.2% | -24.2% | 24.4% | 54.5% | 54.2% | 3.2% | -164.9% | -37.6% | -139.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.4% | -3.4% | 4.6% | 59.1% | 155.2% | 1.6% | -47.1% | -43.9% | — |
| ROA | -2.9% | -2.9% | 4.0% | 48.2% | 113.4% | 1.0% | -24.7% | -9.3% | -22.9% |
| ROIC | -10.5% | -10.5% | 6.8% | 112.2% | 210.2% | -27.5% | -280.4% | — | — |
| ROCE | -6.4% | -6.4% | 3.3% | 77.4% | 217.4% | -6.9% | -30.6% | -14.5% | -28.3% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9.8B exceeds total debt of $254M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.18 | 0.15 | 0.20 | — |
| Debt / EBITDA | — | — | 0.25 | 0.02 | 0.02 | — | — | — | — |
| Net Debt / Equity | — | -0.49 | -0.57 | -0.68 | -0.12 | -0.71 | -0.90 | -1.34 | — |
| Net Debt / EBITDA | — | — | -13.10 | -1.07 | -0.09 | — | — | — | — |
| Debt / FCF | — | — | -2.45 | -1.03 | -1.89 | — | — | — | — |
| Interest Coverage | -99.86 | -99.86 | 88.96 | 799.08 | 2715.05 | -44.21 | -107.17 | -30.30 | -94.06 |
Net cash position: cash ($9.8B) exceeds total debt ($254M)
Short-term solvency ratios and asset-utilisation metrics
BioNTech SE's current ratio of 7.45x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.45 | 7.45 | 9.43 | 7.43 | 4.33 | 2.75 | 4.05 | 3.56 | 1.20 |
| Quick Ratio | 7.34 | 7.34 | 9.26 | 7.28 | 4.18 | 2.64 | 3.97 | 3.51 | 1.17 |
| Cash Ratio | 6.65 | 6.65 | 7.99 | 4.77 | 0.60 | 2.22 | 3.77 | 3.27 | 1.09 |
| Asset Turnover | — | 0.12 | 0.17 | 0.74 | 1.20 | 0.21 | 0.14 | 0.20 | 0.16 |
| Inventory Turnover | 1.91 | 1.91 | 1.68 | 6.81 | 5.79 | 0.93 | 1.44 | 2.36 | 2.40 |
| Days Sales Outstanding | — | 202.18 | 223.62 | 150.68 | 238.16 | 125.25 | 40.04 | 81.37 | 27.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioNTech SE does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | 1.3% | — | — | — | — | — |
| Payout Ratio | — | — | — | 5.1% | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 3.6% | 24.7% | 16.0% | 0.1% | — | — | — |
| FCF Yield | — | — | 18.2% | 35.2% | 1.1% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 2.9% | 2.6% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 2.9% | 3.9% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $240M | $243M | $250M | $260M | $249M | $211M | $227M | $227M |
Compare BNTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BNTXYou | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BNTX stacks up against sector leader Moderna, Inc..
Start ComparisonBioNTech SE's current P/E ratio is -33.7x. The historical average is 12.6x.
BioNTech SE's return on equity (ROE) is -3.4%. The historical average is 18.0%.
Based on historical data, BioNTech SE is trading at a P/E of -33.7x. Compare with industry peers and growth rates for a complete picture.
BioNTech SE has 80.3% gross margin and -47.8% operating margin.